161 related articles for article (PubMed ID: 36286966)
1. [Difficult-to-treat rheumatoid arthritis in real clinical practice. Preliminary results].
Galushko EA; Gordeev AV; Matyanova EV; Olyunin YA; Nasonov EL
Ter Arkh; 2022 Jun; 94(5):661-666. PubMed ID: 36286966
[TBL] [Abstract][Full Text] [Related]
2. Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry.
Jung JY; Lee E; Kim JW; Suh CH; Shin K; Kim J; Kim HA
Arthritis Res Ther; 2023 Sep; 25(1):174. PubMed ID: 37726808
[TBL] [Abstract][Full Text] [Related]
3. Early characterization of difficult-to-treat rheumatoid arthritis by suboptimal initial management: a multicentre cohort study.
Giollo A; Zen M; Larosa M; Astorri D; Salvato M; Calligaro A; Botsios K; Bernardi C; Bianchi G; Doria A
Rheumatology (Oxford); 2023 Jun; 62(6):2083-2089. PubMed ID: 36190344
[TBL] [Abstract][Full Text] [Related]
4. Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry.
Ochi S; Sonomoto K; Nakayamada S; Tanaka Y
Arthritis Res Ther; 2022 Mar; 24(1):61. PubMed ID: 35232462
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis.
Roodenrijs NMT; Hamar A; Kedves M; Nagy G; van Laar JM; van der Heijde D; Welsing PMJ
RMD Open; 2021 Jan; 7(1):. PubMed ID: 33419871
[TBL] [Abstract][Full Text] [Related]
6. Difficult-to-treat rheumatoid arthritis (D2T RA): clinical issues at early stages of disease.
Leon L; Madrid-Garcia A; Lopez-Viejo P; González-Álvaro I; Novella-Navarro M; Freites Nuñez D; Rosales Z; Fernandez-Gutierrez B; Abasolo L
RMD Open; 2023 Mar; 9(1):. PubMed ID: 36889800
[TBL] [Abstract][Full Text] [Related]
7. Clinical and ultrasound features of difficult-to-treat rheumatoid arthritis: A multicenter RA ultrasound cohort study.
Michitsuji T; Fukui S; Morimoto S; Endo Y; Nishino A; Nishihata S; Tsuji Y; Shimizu T; Umeda M; Sumiyoshi R; Koga T; Iwamoto N; Origuchi T; Ueki Y; Yoshitama T; Eiraku N; Matsuoka N; Okada A; Fujikawa K; Ohtsubo H; Takaoka H; Hamada H; Tsuru T; Nawata M; Arinobu Y; Hidaka T; Tada Y; Kawakami A; Kawashiri SY
Scand J Rheumatol; 2024 Mar; 53(2):123-129. PubMed ID: 38085537
[TBL] [Abstract][Full Text] [Related]
8. [Long-term use of glucocorticoids in patients with active rheumatoid arthritis: therapeutic "freeze frame"].
Gordeev AV; Matyanova EV; Galushko EA
Ter Arkh; 2023 Jul; 95(5):380-385. PubMed ID: 38158989
[TBL] [Abstract][Full Text] [Related]
9. Characteristics Of Difficult-To-Treat Psoriatic Arthritis: A Comparative Analysis.
Philippoteaux C; Marty-Ane A; Cailliau E; Labreuche J; Philippe P; Cortet B; Paccou J; Flipo RM; Letarouilly JG
Semin Arthritis Rheum; 2023 Dec; 63():152275. PubMed ID: 37852155
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and variants that predict prognosis of difficult-to-treat rheumatoid arthritis.
Yoshii I; Sawada N; Chijiwa T
Rheumatol Int; 2022 Nov; 42(11):1947-1954. PubMed ID: 35410410
[TBL] [Abstract][Full Text] [Related]
11. Poly-Refractory Rheumatoid Arthritis: An Uncommon Subset of Difficult to Treat Disease With Distinct Inflammatory and Noninflammatory Phenotypes.
David P; Di Matteo A; Hen O; Dass S; Marzo-Ortega H; Wakefield RJ; Bissell LA; Nam J; Mankia K; Emery P; Saleem B; McGonagle D
Arthritis Rheumatol; 2024 Apr; 76(4):510-521. PubMed ID: 38059326
[TBL] [Abstract][Full Text] [Related]
12. Difficult to treat rheumatoid arthritis in a comprehensive evaluation program: frequency according to different objective evaluations.
Garcia-Salinas R; Sanchez-Prado E; Mareco J; Ronald P; Ruta S; Gomez R; Magri S
Rheumatol Int; 2023 Oct; 43(10):1821-1828. PubMed ID: 37269430
[TBL] [Abstract][Full Text] [Related]
13. Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: Analysis from the TRA Clinical Electronic Registry.
Lin CT; Huang WN; Tsai WC; Chen JP; Hung WT; Hsieh TY; Chen HH; Hsieh CW; Lai KL; Tang KT; Tseng CW; Chen DY; Chen YH; Chen YM
PLoS One; 2021; 16(4):e0250877. PubMed ID: 33930048
[TBL] [Abstract][Full Text] [Related]
14. A Review of Difficult-to-Treat Rheumatoid Arthritis: Definition, Clinical Presentation, and Management.
Conran C; Kolfenbach J; Kuhn K; Striebich C; Moreland L
Curr Rheumatol Rep; 2023 Dec; 25(12):285-294. PubMed ID: 37776482
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohort.
Watanabe R; Hashimoto M; Murata K; Murakami K; Tanaka M; Ohmura K; Ito H; Matsuda S
Immunol Med; 2022 Mar; 45(1):35-44. PubMed ID: 34033729
[TBL] [Abstract][Full Text] [Related]
16. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
[TBL] [Abstract][Full Text] [Related]
17. Difficult-to-treat rheumatoid arthritis: Current concept and unsolved problems.
Watanabe R; Okano T; Gon T; Yoshida N; Fukumoto K; Yamada S; Hashimoto M
Front Med (Lausanne); 2022; 9():1049875. PubMed ID: 36353219
[TBL] [Abstract][Full Text] [Related]
18. 'Difficult to treat' rheumatoid arthritis: current position and considerations for next steps.
Tan Y; Buch MH
RMD Open; 2022 Jul; 8(2):. PubMed ID: 35896282
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
20. Healthcare utilization and economic burden of difficult-to-treat rheumatoid arthritis: a cost-of-illness study.
Roodenrijs NMT; Welsing PMJ; van der Goes MC; Tekstra J; Lafeber FPJG; Jacobs JWG; van Laar JM
Rheumatology (Oxford); 2021 Oct; 60(10):4681-4690. PubMed ID: 33502493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
